Evidence map›Paper›PMID 41576103›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Chronic and acute modulator treatment restore wild-type-like activity and stability to the primary cystic fibrosis-causing

Mayuree Rodrat, James N Charlick, David N Sheppard

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Chronic and acute modulator treatment restore wild-type-like activity and stability to the primary cystic fibrosis-causingProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mayuree RodratSchool of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol BS8 1TD, United Kingdom.ORCID 0000-0003-2062-8682
James N CharlickSchool of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol BS8 1TD, United Kingdom.ORCID 0000-0001-9798-7769
David N SheppardSchool of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol BS8 1TD, United Kingdom.ORCID 0000-0001-5533-9130

Funding

Cystic Fibrosis Trust (CF) SRC 021
6 · The paper itself

Abstract

Elexacaftor-tezacaftor-ivacaftor has transformed the treatment of people with cystic fibrosis (CF) and the predominant cystic fibrosis transmembrane conductance regulator (

Indexed as

AminophenolsBenzodioxolesCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorIndolesQuinolonesChloride Channel AgonistsDrug CombinationsHumansMutationPatch-Clamp TechniquesPyrazolesPyridinesPyrrolidinesQuinolinesAminophenolsBenzodioxolesCFTR protein, humanChloride Channel AgonistsCystic Fibrosis Transmembrane Conductance RegulatorDrug Combinationselexacaftorelexacaftor, ivacaftor, tezacaftor drug combinationIndolesivacaftorPyrazolesPyridinesPyrrolidinesQuinolinesQuinolonestezacaftortezacaftor, ivacaftor drug combinationCFTR chloride ion channelcystic fibrosiselexacaftor-tezacaftor-ivacaftorF508del-CFTR

Identifiers

PMID41576103
PMCPMC12867690

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.